关于喉部基底样鳞状细胞癌预后调查的复函编辑。

Head & Neck Pub Date : 2014-10-01 Epub Date: 2014-08-28 DOI:10.1002/hed.23769
Valerie Fritsch, Eric Lentsch
{"title":"关于喉部基底样鳞状细胞癌预后调查的复函编辑。","authors":"Valerie Fritsch, Eric Lentsch","doi":"10.1002/hed.23769","DOIUrl":null,"url":null,"abstract":"To the Editor: I read with great interest the recent article by Fritsch and Lentsch, who investigated laryngeal basaloid squamous cell carcinoma (BSCC) prognosis using the populationbased cancer registries of the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. Although the study by Fritsch and Lentsch is inevitably characterized by a potential bias relating to the fact that the cases of BSCC were diagnosed and treated by different teams and in different ways, the numerosity of the cases considered is remarkable. These studies are important, particularly those comparing the prognosis for head and neck BSCC as opposed to conventional squamous cell carcinoma (SCC) in site-matched and stage-matched settings, because numerous—but not all—investigators currently believe that head and neck BSCC is a significantly more aggressive lesion and carries a worse prognosis than the more commonly encountered SCC. Confirmation of the greater aggressiveness of head and neck BSCC visa-vis conventional SCC could rationally justify a more aggressive approach to their locoregional treatment and possibly the use of adjuvant chemotherapy in head and neck BSCC. However, because the mistakes made (and reiterated) in citations eventually have a significant impact on the international medical literature, I have to point out that, in their reference number 22, Fritsch and Lentsch misquote the content of a study conducted by our group in this field. In the investigation concerned, the 9 BSCCs considered did not all arise in the larynx (but 5 in the larynx, 3 in the tongue, and 1 in the tonsil), whereas another study by our group analyzed the prognostic role of the apoptosis inhibitor protein survivin in 9 consecutive cases of laryngeal BSCC, and, in this latter series, the diseasespecific survival (DSS) was 55.6%. In speaking about the prognosis for BSCC of the head and neck, it is extremely important to be accurate about the site involved by the primary lesion. In fact, a more recent study by Fritsch and Lentsch concluded that the DSS of patients treated for laryngeal BSCC was significantly lower than for patients with conventional SCC on multivariate analysis, but patients with oropharyngeal BSCC had a higher DSS than those with oropharyngeal conventional SCC (reported data source: Surveillance, Epidemiology, and End Results Program of the National Cancer Institute, September 2005; size of the populations considered: 1083 head and neck BSCCs, 66,929 conventional SCC).","PeriodicalId":501638,"journal":{"name":"Head & Neck","volume":" ","pages":"1527-8"},"PeriodicalIF":0.0000,"publicationDate":"2014-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/hed.23769","citationCount":"0","resultStr":"{\"title\":\"Reply to letter to the editor regarding investigation of laryngeal basaloid squamous cell carcinoma prognosis.\",\"authors\":\"Valerie Fritsch, Eric Lentsch\",\"doi\":\"10.1002/hed.23769\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"To the Editor: I read with great interest the recent article by Fritsch and Lentsch, who investigated laryngeal basaloid squamous cell carcinoma (BSCC) prognosis using the populationbased cancer registries of the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. Although the study by Fritsch and Lentsch is inevitably characterized by a potential bias relating to the fact that the cases of BSCC were diagnosed and treated by different teams and in different ways, the numerosity of the cases considered is remarkable. These studies are important, particularly those comparing the prognosis for head and neck BSCC as opposed to conventional squamous cell carcinoma (SCC) in site-matched and stage-matched settings, because numerous—but not all—investigators currently believe that head and neck BSCC is a significantly more aggressive lesion and carries a worse prognosis than the more commonly encountered SCC. Confirmation of the greater aggressiveness of head and neck BSCC visa-vis conventional SCC could rationally justify a more aggressive approach to their locoregional treatment and possibly the use of adjuvant chemotherapy in head and neck BSCC. However, because the mistakes made (and reiterated) in citations eventually have a significant impact on the international medical literature, I have to point out that, in their reference number 22, Fritsch and Lentsch misquote the content of a study conducted by our group in this field. In the investigation concerned, the 9 BSCCs considered did not all arise in the larynx (but 5 in the larynx, 3 in the tongue, and 1 in the tonsil), whereas another study by our group analyzed the prognostic role of the apoptosis inhibitor protein survivin in 9 consecutive cases of laryngeal BSCC, and, in this latter series, the diseasespecific survival (DSS) was 55.6%. In speaking about the prognosis for BSCC of the head and neck, it is extremely important to be accurate about the site involved by the primary lesion. In fact, a more recent study by Fritsch and Lentsch concluded that the DSS of patients treated for laryngeal BSCC was significantly lower than for patients with conventional SCC on multivariate analysis, but patients with oropharyngeal BSCC had a higher DSS than those with oropharyngeal conventional SCC (reported data source: Surveillance, Epidemiology, and End Results Program of the National Cancer Institute, September 2005; size of the populations considered: 1083 head and neck BSCCs, 66,929 conventional SCC).\",\"PeriodicalId\":501638,\"journal\":{\"name\":\"Head & Neck\",\"volume\":\" \",\"pages\":\"1527-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/hed.23769\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Head & Neck\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/hed.23769\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2014/8/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Head & Neck","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/hed.23769","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/8/28 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
Reply to letter to the editor regarding investigation of laryngeal basaloid squamous cell carcinoma prognosis.
To the Editor: I read with great interest the recent article by Fritsch and Lentsch, who investigated laryngeal basaloid squamous cell carcinoma (BSCC) prognosis using the populationbased cancer registries of the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. Although the study by Fritsch and Lentsch is inevitably characterized by a potential bias relating to the fact that the cases of BSCC were diagnosed and treated by different teams and in different ways, the numerosity of the cases considered is remarkable. These studies are important, particularly those comparing the prognosis for head and neck BSCC as opposed to conventional squamous cell carcinoma (SCC) in site-matched and stage-matched settings, because numerous—but not all—investigators currently believe that head and neck BSCC is a significantly more aggressive lesion and carries a worse prognosis than the more commonly encountered SCC. Confirmation of the greater aggressiveness of head and neck BSCC visa-vis conventional SCC could rationally justify a more aggressive approach to their locoregional treatment and possibly the use of adjuvant chemotherapy in head and neck BSCC. However, because the mistakes made (and reiterated) in citations eventually have a significant impact on the international medical literature, I have to point out that, in their reference number 22, Fritsch and Lentsch misquote the content of a study conducted by our group in this field. In the investigation concerned, the 9 BSCCs considered did not all arise in the larynx (but 5 in the larynx, 3 in the tongue, and 1 in the tonsil), whereas another study by our group analyzed the prognostic role of the apoptosis inhibitor protein survivin in 9 consecutive cases of laryngeal BSCC, and, in this latter series, the diseasespecific survival (DSS) was 55.6%. In speaking about the prognosis for BSCC of the head and neck, it is extremely important to be accurate about the site involved by the primary lesion. In fact, a more recent study by Fritsch and Lentsch concluded that the DSS of patients treated for laryngeal BSCC was significantly lower than for patients with conventional SCC on multivariate analysis, but patients with oropharyngeal BSCC had a higher DSS than those with oropharyngeal conventional SCC (reported data source: Surveillance, Epidemiology, and End Results Program of the National Cancer Institute, September 2005; size of the populations considered: 1083 head and neck BSCCs, 66,929 conventional SCC).
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信